The recent pathological classification of gliomas has been changed to take into account both classical histopathology and key genetic changes, such as IDH1 mutant status, which predicts a better prognosis, and the presence or absence of 1p/19q co-deletions, TERT promoter mutations, and ATRX mutations [21,22]. Here, IDH1 is linked to central nervous system cancer.